For US Healthcare Professionals

Welcome to the
axSpA tour

Journey through 3 exhibits that explore pathobiology, clinical manifestations, and disease outcome measures used in clinical practice.

Gaze into the Gallery of Cytokines

Explore the pathobiology of axSpA

Through eye-catching modern art, discover the latest science on key immune cells and cytokines involved in the pathobiology of axSpA.

The pathogenesis of axSpA involves multiple factors, including environmental and genetic susceptibility, and inflammatory, innate, and adaptive immune responses, including cytokine dysregulation.1,2

See the axSpA exhibit to uncover the science.

axSpA=axial spondyloarthritis

Take your seats in the Animated Science Theatre

Uncover the mechanisms driving axSpA, including the role of IL-17A and IL-17F, TNF, and IL-23

A glimpse into the hall of statues

Examine the clinical manifestations of axSpA

AxSpA is associated with a substantial burden of disease. Its associated clinical manifestations can affect a patient’s quality of life and have been linked with signs and symptoms such as chronic pain, deformities, and reduced function.1,3

See the axSpA exhibit to explore the hall of statues.

Peruse the disease outcome collection

Discover the disease outcome measures of axSpA

Experience transformative sculptural collages depicting disease outcome measures and learn about their evolving importance in defining and monitoring disease activity.

The decision-making pathway for clinicians is complex, and many patients are not reaching optimal disease outcome goals.4,5 An array of different disease outcome measures has been developed to define and monitor the impact of axSpA—including both composite and domain-specific measures.6-8

Tour the axSpA exhibit to learn more.

  1. Furst DE and Louie JA. Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):135
  2. Silvagni E, Missiroli S, Perrone M, et al. From bed to bench and back: TNF-α, IL-23/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis. Front Pharmacol. 2021;12:672515
  3. Ogdie A, Hur P, Liu M, et al. Impact of multidomain disease presentations on patients with psoriatic arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021;48(5):698-706
  4. Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: A review of the literature. J Rheumatol. 2018;45(1)6-13
  5. D’Angelo S, Salvarani C, Marando F, et al. Residual disease in patients with axial spondyloarthritis: A post-hoc analysis of the QUASAR study. J Clin Med. 2022;11:3553
  6. Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken). Oct 2020;72(Suppl 10):82-109
  7. Mease PJ. Measures of psoriatic arthritis. Arthritis Care Res (Hoboken). Nov 2011;63 Suppl 11:S64-85
  8. Ogdie A, Duarte-García A, Hwang M, et al. Measuring outcomes in axial spondyloarthritis. Arthritis Care Res. 2020;72(Suppl 10):47-71